Merck-Kelun ADC scores survival win in Phase 3 stomach cancer trial
Licensed from Kelun-Biotech, Merck’s TROP2-targeting antibody drug conjugate sac-TMT improved overall survival in advanced gastroesophageal cancer while missing on two secondary endpoints.
comments(0)
5-min edit window · permanent after that